MedCap (OM:MCAP) Stock Faces A Valuation Debate After Q3 Earnings

MedCap stock closed at SEK600.5 on Friday after its Q3 2026 report, a level that already prices in a strong run over the past three months. The headline this quarter is earnings power. Basic earnings per share reached 5.66 SEK and net income came in at SEK84.8m, reinforcing a profit story that now shows 39.3% growth over the past year and a higher trailing net margin of 11.5%.

Short term traders may focus on the lofty 32.8x P/E. Long term holders are more likely to zoom out to the multi year growth profile and the discounted cash flow value that sits above today’s price.

Impressed by MedCap’s earnings strength but unsure about paying a 32.8x P/E for it? Compare that profile with other solid operators using our list of solid balance sheet and fundamentals stocks (204 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): SEK 608m vs SEK 501.5m (up 21.2%)
• Net Income (Q3 2026 vs Q3 2025): SEK 84.8m vs SEK 51.2m (up 65.6%)
• Basic EPS (Q3 2026 vs Q3 2025): 5.66 SEK vs 3.42 SEK (up 65.7%)
• Net Profit Margin (Trailing 12 Months vs Prior Year): 11.5% vs 9.9% (margin higher by 1.6 percentage points)

Earnings tell you how profitable MedCap looked this quarter, but investors who care about what they are really paying tend to follow the cash that actually comes in and out of the business.

When you line up MedCap's reported cash flows against the current share price, the numbers in the valuation model suggest the stock could be a striking 35% undervalued.

MedCap earnings momentum and the bullish story

For anyone leaning bullish on MedCap, this quarter’s mix of numbers gives that view some backing. Revenue of SEK608m against SEK501.5m and net income of SEK84.8m versus SEK51.2m both point in the same direction. Profitability looks firmer as well, with basic EPS moving from 3.42 SEK to 5.66 SEK and the trailing net margin at 11.5% compared with 9.9%. For a healthcare focused investment platform, that combination of higher earnings power and thicker margins supports the idea that the underlying model is working, at least right now.

Where the MedCap bear case still bites

There is still ammunition for a cautious view on MedCap. Earnings are rising faster than revenue, which can reflect mix benefits that may not repeat. The business also invests in smaller, often illiquid healthcare assets where visibility is limited, so headline margin expansion to 11.5% from 9.9% does not fully answer questions about portfolio resilience. Recent share price gains over 7, 30 and 90 days show investors reacting positively, yet that reaction does not remove the complexity or execution risk embedded in a listed private equity style structure.

Reveal where the surface looks calm, but the models start to disagree on MedCap’s next few years. Access the analyst estimates for MedCap.

Hunt For Mispriced Earnings Power

MedCap’s earnings print and valuation debate show how quickly sentiment can swing around a solid operator. The real opportunity is finding stocks that could be undervalued before the market corrects them.

• Company 1 - 24% below our estimate - expand performing loan books in faster growing segments while relying on stable retail deposits for funding.
• Company 2 - 25% below our estimate - scale complex generic portfolios outside the U.S. as rising operating cash flow helps support regulatory filings and manage leverage.
• Company 3 - 23% below our estimate - ramp higher margin healthcare components while a cost program and capsule acquisition shift the mix toward more profitable contracts.

Those are three of them. See all 195 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com